{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:26:44Z","timestamp":1791404804975,"version":"4.3.3"},"reference-count":124,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T00:00:00Z","timestamp":1631145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T00:00:00Z","timestamp":1631145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s11899-021-00643-3","type":"journal-article","created":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T12:03:33Z","timestamp":1631189013000},"page":"405-417","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Management and Outcomes of Blast Transformed Chronic Myelomonocytic Leukemia"],"prefix":"10.1007","volume":"16","author":[{"given":"Danielle","family":"Hammond","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Montalban-Bravo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,9]]},"reference":[{"issue":"9","key":"643_CR1","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1200\/JCO.1988.6.9.1417","volume":"6","author":"P Fenaux","year":"1988","unstructured":"Fenaux P, et al. Prognostic factors in adult chronic myelomonocytic leukemia: an analysis of 107 cases. J Clin Oncol. 1988;6(9):1417\u201324.","journal-title":"J Clin Oncol"},{"issue":"10","key":"643_CR2","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/S0025-6196(12)61287-7","volume":"64","author":"A Tefferi","year":"1989","unstructured":"Tefferi A, et al. Chronic myelomonocytic leukemia: natural history and prognostic determinants. Mayo Clin Proc. 1989;64(10):1246\u201354.","journal-title":"Mayo Clin Proc"},{"issue":"19","key":"643_CR3","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1200\/JCO.2012.47.3314","volume":"31","author":"R Itzykson","year":"2013","unstructured":"Itzykson R, et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol. 2013;31(19):2428\u201336.","journal-title":"J Clin Oncol"},{"issue":"7","key":"643_CR4","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1038\/leu.2013.88","volume":"27","author":"MM Patnaik","year":"2013","unstructured":"Patnaik MM, et al. Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. Leukemia. 2013;27(7):1504\u201310.","journal-title":"Leukemia"},{"issue":"15","key":"643_CR5","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1182\/blood-2012-08-452938","volume":"121","author":"E Such","year":"2013","unstructured":"Such E, et al. Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. Blood. 2013;121(15):3005\u201315.","journal-title":"Blood"},{"issue":"8","key":"643_CR6","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.clml.2017.06.029","volume":"17","author":"A Rivera Duarte","year":"2017","unstructured":"Rivera Duarte A, et al. Blastic Transformation in Mexican Population With Chronic Myelomonocytic Leukemia. Clin Lymphoma Myeloma Leuk. 2017;17(8):532\u20138.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"643_CR7","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/ajh.24735","volume":"92","author":"A Alfonso","year":"2017","unstructured":"Alfonso A, et al. Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents. Am J Hematol. 2017;92(7):599\u2013606.","journal-title":"Am J Hematol"},{"issue":"2","key":"643_CR8","doi-asserted-by":"publisher","first-page":"e135","DOI":"10.1016\/S2352-3026(20)30374-4","volume":"8","author":"L Pleyer","year":"2021","unstructured":"Pleyer L, et al. Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study. Lancet Haematol. 2021;8(2):e135\u201348.","journal-title":"Lancet Haematol"},{"issue":"7","key":"643_CR9","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/ajh.25488","volume":"94","author":"T Coston","year":"2019","unstructured":"Coston T, et al. Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients. Am J Hematol. 2019;94(7):767\u201379.","journal-title":"Am J Hematol"},{"issue":"20","key":"643_CR10","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391\u2013405.","journal-title":"Blood"},{"issue":"12","key":"643_CR11","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.1038\/s41375-018-0186-x","volume":"32","author":"E Margolskee","year":"2018","unstructured":"Margolskee E. So-called \u201cblast phase\u201d of chronic myelomonocytic leukemia: a plea for uniform terminology. Leukemia. 2018;32(12):2716.","journal-title":"Leukemia"},{"issue":"31","key":"643_CR12","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.1200\/JCO.2014.60.0890","volume":"33","author":"LS Granfeldt Ostgard","year":"2015","unstructured":"Granfeldt Ostgard LS, et al. Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study. J Clin Oncol. 2015;33(31):3641\u20139.","journal-title":"J Clin Oncol"},{"issue":"12","key":"643_CR13","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1182\/blood-2014-10-607341","volume":"125","author":"MR Savona","year":"2015","unstructured":"Savona MR, et al. An international consortium proposal of uniform response criteria for myelodysplastic\/myeloproliferative neoplasms (MDS\/MPN) in adults. Blood. 2015;125(12):1857\u201365.","journal-title":"Blood"},{"issue":"6","key":"643_CR14","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/modpathol.2012.218","volume":"26","author":"EL Courville","year":"2013","unstructured":"Courville EL, et al. Clinicopathologic analysis of acute myeloid leukemia arising from chronic myelomonocytic leukemia. Mod Pathol. 2013;26(6):751\u201361.","journal-title":"Mod Pathol"},{"key":"643_CR15","doi-asserted-by":"crossref","unstructured":"Beran M, et al. Prognostic factors and risk assessment in chronic myelomonocytic leukemia: validation study of the M.D. Anderson Prognostic Scoring System. Leuk Lymphoma. 2007;48(6): 1150-60.","DOI":"10.1080\/10428190701216386"},{"issue":"10","key":"643_CR16","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1182\/blood-2016-05-714030","volume":"128","author":"C Elena","year":"2016","unstructured":"Elena C, et al. Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. Blood. 2016;128(10):1408\u201317.","journal-title":"Blood"},{"issue":"5","key":"643_CR17","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/ajh.23962","volume":"90","author":"MM Patnaik","year":"2015","unstructured":"Patnaik MM, et al. Blast transformation in chronic myelomonocytic leukemia: Risk factors, genetic features, survival, and treatment outcome. Am J Hematol. 2015;90(5):411\u20136.","journal-title":"Am J Hematol"},{"key":"643_CR18","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1038\/bcj.2014.90","volume":"5","author":"MM Patnaik","year":"2015","unstructured":"Patnaik MM, et al. Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome. Blood Cancer J. 2015;5:e270.","journal-title":"Blood Cancer J."},{"issue":"11","key":"643_CR19","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1038\/s41375-018-0143-8","volume":"32","author":"MM Patnaik","year":"2018","unstructured":"\u2022\u2022 Patnaik MM, et al. Blast phase chronic myelomonocytic leukemia: Mayo-MDACC collaborative study of 171 cases. Leukemia. 2018;32(11):2512\u20138. Largest cohort to date establishing benchmark outcomes in this rare patient group.","journal-title":"Leukemia"},{"issue":"8","key":"643_CR20","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1002\/ajh.23751","volume":"89","author":"G Tang","year":"2014","unstructured":"Tang G, et al. Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution. Am J Hematol. 2014;89(8):813\u20138.","journal-title":"Am J Hematol"},{"issue":"12","key":"643_CR21","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1002\/ajh.23846","volume":"89","author":"EA Wassie","year":"2014","unstructured":"Wassie EA, et al. Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic-French Consortium Study. Am J Hematol. 2014;89(12):1111\u20135.","journal-title":"Am J Hematol"},{"issue":"8","key":"643_CR22","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1158\/1078-0432.CCR-09-2112","volume":"16","author":"C Ricci","year":"2010","unstructured":"Ricci C, et al. RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant. Clin Cancer Res. 2010;16(8):2246\u201356.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"643_CR23","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.jmoldx.2018.07.002","volume":"20","author":"RF McClure","year":"2018","unstructured":"McClure RF, et al. Clinical significance of DNA variants in chronic myeloid neoplasms: a report of the association for molecular pathology. J Mol Diagn. 2018;20(6):717\u201337.","journal-title":"J Mol Diagn"},{"issue":"12","key":"643_CR24","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1038\/leu.2017.164","volume":"31","author":"BJ Patel","year":"2017","unstructured":"Patel BJ, et al. Genomic determinants of chronic myelomonocytic leukemia. Leukemia. 2017;31(12):2815\u201323.","journal-title":"Leukemia"},{"issue":"1","key":"643_CR25","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1038\/s41467-021-23186-w","volume":"12","author":"RM Carr","year":"2021","unstructured":"\u2022\u2022 Carr RM, et al. RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis. Nat Commun. 2021;12(1):2901. Critical translational concept that is the basis of dual MEK\/PLK1 inhibition in RAS-mutated CMML and CMML-BP.","journal-title":"Nat Commun"},{"issue":"4","key":"643_CR26","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/j.1365-2141.2010.08381.x","volume":"151","author":"V Gelsi-Boyer","year":"2010","unstructured":"Gelsi-Boyer V, et al. ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. Br J Haematol. 2010;151(4):365\u201375.","journal-title":"Br J Haematol"},{"key":"643_CR27","doi-asserted-by":"publisher","first-page":"e385","DOI":"10.1038\/bcj.2015.113","volume":"6","author":"MM Patnaik","year":"2016","unstructured":"Patnaik MM, et al. Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia. Blood Cancer J. 2016;6:e385.","journal-title":"Blood Cancer J."},{"issue":"8","key":"643_CR28","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1038\/leu.2009.48","volume":"23","author":"MC Kuo","year":"2009","unstructured":"Kuo MC, et al. RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation. Leukemia. 2009;23(8):1426\u201331.","journal-title":"Leukemia"},{"issue":"15","key":"643_CR29","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.1158\/1078-0432.CCR-14-2203","volume":"21","author":"SC Tsai","year":"2015","unstructured":"Tsai SC, et al. Biological Activities of RUNX1 mutants predict secondary acute leukemia transformation from chronic myelomonocytic leukemia and myelodysplastic Syndromes. Clin Cancer Res. 2015;21(15):3541\u201351.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"643_CR30","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13045-019-0789-3","volume":"12","author":"R Bera","year":"2019","unstructured":"Bera R, et al. RUNX1 mutations promote leukemogenesis of myeloid malignancies in ASXL1-mutated leukemia. J Hematol Oncol. 2019;12(1):104.","journal-title":"J Hematol Oncol"},{"key":"643_CR31","doi-asserted-by":"crossref","unstructured":"Marinaccio C, et al. LKB1\/STK11 is a tumor suppressor in the progression of myeloproliferative neoplasms. Cancer Discov. 2021;11(6):1398\u2013410.","DOI":"10.1158\/2159-8290.CD-20-1353"},{"issue":"5","key":"643_CR32","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1038\/s41375-019-0690-7","volume":"34","author":"G Coltro","year":"2020","unstructured":"Coltro G, et al. Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients. Leukemia. 2020;34(5):1407\u201321.","journal-title":"Leukemia"},{"issue":"9","key":"643_CR33","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","volume":"125","author":"RC Lindsley","year":"2015","unstructured":"Lindsley RC, et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015;125(9):1367\u201376.","journal-title":"Blood"},{"issue":"4","key":"643_CR34","doi-asserted-by":"crossref","first-page":"e292","DOI":"10.1097\/HS9.0000000000000292","volume":"3","author":"SM Johnson","year":"2019","unstructured":"Johnson SM, et al. Acute Myeloid Leukemia with Co-mutated ASXL1 and SRSF2 Exhibits Monocytic Differentiation and has a Mutational Profile Overlapping with Chronic Myelomonocytic Leukemia. Hemasphere. 2019;3(4):e292.","journal-title":"Hemasphere."},{"key":"643_CR35","doi-asserted-by":"crossref","unstructured":"Richardson DR, et al. Genomic characteristics and prognostic significance of co-mutated ASXL1\/SRSF2 acute myeloid leukemia. Am J Hematol. 2021.","DOI":"10.1002\/ajh.26110"},{"issue":"3","key":"643_CR36","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1182\/bloodadvances.2019001101","volume":"4","author":"G Montalban-Bravo","year":"2020","unstructured":"Montalban-Bravo G, et al. Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. Blood Adv. 2020;4(3):482\u201395.","journal-title":"Blood Adv"},{"key":"643_CR37","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.leukres.2018.05.012","volume":"70","author":"W Wang","year":"2018","unstructured":"Wang W, et al. Characterization of chronic myelomonocytic leukemia with TP53 mutations. Leuk Res. 2018;70:97\u20139.","journal-title":"Leuk Res"},{"issue":"1","key":"643_CR38","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/ejh.12549","volume":"96","author":"J Peng","year":"2016","unstructured":"Peng J, et al. Chronic myelomonocytic leukemia with nucleophosmin (NPM1) mutation. Eur J Haematol. 2016;96(1):65\u201371.","journal-title":"Eur J Haematol"},{"issue":"6","key":"643_CR39","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1182\/bloodadvances.2018026989","volume":"3","author":"G Montalban-Bravo","year":"2019","unstructured":"Montalban-Bravo G, et al. NPM1 mutations define a specific subgroup of MDS and MDS\/MPN patients with favorable outcomes with intensive chemotherapy. Blood Adv. 2019;3(6):922\u201333.","journal-title":"Blood Adv"},{"issue":"2","key":"643_CR40","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1172\/JCI129126","volume":"130","author":"S Klossowski","year":"2020","unstructured":"Klossowski S, et al. Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia. J Clin Invest. 2020;130(2):981\u201397.","journal-title":"J Clin Invest"},{"issue":"3","key":"643_CR41","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/leu.2011.253","volume":"26","author":"A Tefferi","year":"2012","unstructured":"Tefferi A, et al. IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F. Leukemia. 2012;26(3):475\u201380.","journal-title":"Leukemia"},{"issue":"Supplement 1","key":"643_CR42","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1182\/blood-2020-139901","volume":"136","author":"V Guerra","year":"2020","unstructured":"Guerra V, et al. Outcomes of Chronic Myelomonocytic Leukemia (CMML) after Hypomethylating Agent (HMA) Failure. Blood. 2020;136(Supplement 1):22\u20133.","journal-title":"Blood"},{"issue":"10","key":"643_CR43","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1038\/s41375-019-0447-3","volume":"33","author":"N Lucas","year":"2019","unstructured":"\u2022 Lucas N, et al. Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia. Leukemia. 2019;33(10):2466\u201380. Cooperative role of pDCs in CMML progression is an important new concept providing the basis for targeting the CD123\/pDC axis.","journal-title":"Leukemia"},{"issue":"20","key":"643_CR44","doi-asserted-by":"publisher","first-page":"5188","DOI":"10.1158\/0008-5472.CAN-11-3468","volume":"72","author":"V Sisirak","year":"2012","unstructured":"Sisirak V, et al. Impaired IFN-alpha production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression. Cancer Res. 2012;72(20):5188\u201397.","journal-title":"Cancer Res"},{"issue":"1","key":"643_CR45","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.leukres.2011.05.003","volume":"36","author":"RA Mathew","year":"2012","unstructured":"Mathew RA, et al. Cutaneous manifestations in CMML: Indication of disease acceleration or transformation to AML and review of the literature. Leuk Res. 2012;36(1):72\u201380.","journal-title":"Leuk Res"},{"issue":"9","key":"643_CR46","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1097\/PAS.0b013e31825dd4de","volume":"36","author":"F Vitte","year":"2012","unstructured":"Vitte F, et al. Specific skin lesions in chronic myelomonocytic leukemia: a spectrum of myelomonocytic and dendritic cell proliferations: a study of 42 cases. Am J Surg Pathol. 2012;36(9):1302\u201316.","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"643_CR47","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1038\/leu.2017.38","volume":"31","author":"L Brunetti","year":"2017","unstructured":"Brunetti L, et al. Blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia: a shared clonal origin. Leukemia. 2017;31(5):1238\u201340.","journal-title":"Leukemia"},{"issue":"9","key":"643_CR48","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41408-018-0120-5","volume":"8","author":"MM Patnaik","year":"2018","unstructured":"Patnaik MM, et al. Biallelic inactivation of the retinoblastoma gene results in transformation of chronic myelomonocytic leukemia to a blastic plasmacytoid dendritic cell neoplasm: shared clonal origins of two aggressive neoplasms. Blood Cancer J. 2018;8(9):82.","journal-title":"Blood Cancer J"},{"key":"643_CR49","doi-asserted-by":"publisher","first-page":"10767","DOI":"10.1038\/ncomms10767","volume":"7","author":"J Merlevede","year":"2016","unstructured":"Merlevede J, et al. Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents. Nat Commun. 2016;7:10767.","journal-title":"Nat Commun"},{"issue":"Supplement 1","key":"643_CR50","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1182\/blood-2020-138680","volume":"136","author":"R Itzykson","year":"2020","unstructured":"Itzykson R, et al. Decitabine Versus Hydroxyurea for Advanced Proliferative CMML: Results of the Emsco Randomized Phase 3 Dacota Trial. Blood. 2020;136(Supplement 1):53\u20134.","journal-title":"Blood"},{"issue":"11","key":"643_CR51","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41408-020-00387-y","volume":"10","author":"P Pophali","year":"2020","unstructured":"\u2022\u2022 Pophali P, et al. Prognostic impact and timing considerations for allogeneic hematopoietic stem cell transplantation in chronic myelomonocytic leukemia. Blood Cancer J. 2020;10(11):121. Provides historical benchmark for post transplant outcomes in CMML and CMML-BP.","journal-title":"Blood Cancer J"},{"issue":"26","key":"643_CR52","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","volume":"36","author":"JE Lancet","year":"2018","unstructured":"\u2022 Lancet JE, et al. CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. J Clin Oncol. 2018;36(26):2684\u201392. One of the few existing studies of novel therapy explicitly reporting outcomes in CMML-BP.","journal-title":"J Clin Oncol"},{"key":"643_CR53","doi-asserted-by":"crossref","unstructured":"Lancet, JE, et al. Five-year final results of a phase III study of CPX-351 versus 7+3 in older adults with newly diagnosed high-risk\/secondary AML. J Clin Oncol. 2020. 38(15_suppl): 7510.","DOI":"10.1200\/JCO.2020.38.15_suppl.7510"},{"issue":"1","key":"643_CR54","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1182\/bloodadvances.2020003159","volume":"5","author":"E Chiche","year":"2021","unstructured":"Chiche E, et al. Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort. Blood Adv. 2021;5(1):176\u201384.","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"643_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1182\/blood-2020-139942","volume":"136","author":"G Montalban Bravo","year":"2020","unstructured":"Montalban Bravo G, et al. Initial results of a phase 1 dose escalation study of CPX-351 for patients with Int-2 or high risk IPSS myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) after failure to hypomethylating agents. Blood. 2020;136(Supplement 1):1\u20133.","journal-title":"Blood"},{"issue":"1","key":"643_CR56","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/ajh.23862","volume":"90","author":"CW Freyer","year":"2015","unstructured":"Freyer CW, et al. Revisiting the role of cladribine in acute myeloid leukemia: an improvement on past accomplishments or more old news? Am J Hematol. 2015;90(1):62\u201372.","journal-title":"Am J Hematol"},{"issue":"4","key":"643_CR57","doi-asserted-by":"publisher","first-page":"298","DOI":"10.3816\/CLM.2009.n.058","volume":"9","author":"MG Martin","year":"2009","unstructured":"Martin MG, et al. Cladribine in the treatment of acute myeloid leukemia: a single-institution experience. Clin Lymphoma Myeloma. 2009;9(4):298\u2013301.","journal-title":"Clin Lymphoma Myeloma"},{"issue":"4","key":"643_CR58","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.leukres.2013.12.010","volume":"38","author":"MV Jaglal","year":"2014","unstructured":"Jaglal MV, et al. Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure. Leuk Res. 2014;38(4):443\u20136.","journal-title":"Leuk Res"},{"key":"643_CR59","doi-asserted-by":"publisher","first-page":"106367","DOI":"10.1016\/j.leukres.2020.106367","volume":"93","author":"C Talati","year":"2020","unstructured":"Talati C, et al. Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancy. Leuk Res. 2020;93:106367.","journal-title":"Leuk Res."},{"key":"643_CR60","doi-asserted-by":"crossref","unstructured":"Przespolewski, A., et al., Cladribine, cytarabine, and GCSF with and without mitoxantrone (CLAG +\/- M) is highly effective for poor risk acute myeloid leukemia with adverse karyotype and prior hypomethylating therapy. Leuk Lymphoma. 2021: 1-6.","DOI":"10.1080\/10428194.2021.1885654"},{"issue":"9","key":"643_CR61","doi-asserted-by":"publisher","first-page":"e411","DOI":"10.1016\/S2352-3026(18)30132-7","volume":"5","author":"TM Kadia","year":"2018","unstructured":"Kadia TM, et al. Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. Lancet Haematol. 2018;5(9):e411\u201321.","journal-title":"Lancet Haematol"},{"key":"643_CR62","doi-asserted-by":"crossref","unstructured":"Kadia T. Phase II study of venetoclax added to cladribine + low dose AraC (LDAC) alternating with 5-azacytidine demonstrates high rates of minimal residual disease (MRD) negative complete remissions (CR) and excellent tolerability in older patients with newly diagnosed acute myeloid leukemia (AML). 2020.","DOI":"10.1182\/blood-2020-142092"},{"issue":"10","key":"643_CR63","first-page":"1563","volume":"10","author":"SM Kornblau","year":"1996","unstructured":"Kornblau SM, et al. Clinical and laboratory studies of 2-chlorodeoxyadenosine +\/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults. Leukemia. 1996;10(10):1563\u20139.","journal-title":"Leukemia"},{"issue":"5","key":"643_CR64","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1172\/JCI114865","volume":"86","author":"CJ Carrera","year":"1990","unstructured":"Carrera CJ, et al. Potent toxicity of 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo A novel approach to immunosuppressive therapy. J Clin Invest. 1990;86(5):1480\u20138.","journal-title":"J Clin Invest."},{"issue":"2","key":"643_CR65","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/cei.12109","volume":"173","author":"V Singh","year":"2013","unstructured":"Singh V, et al. 2-Chlorodeoxyadenosine (cladribine) induces apoptosis in human monocyte-derived dendritic cells. Clin Exp Immunol. 2013;173(2):288\u201397.","journal-title":"Clin Exp Immunol"},{"issue":"21","key":"643_CR66","doi-asserted-by":"publisher","first-page":"5076","DOI":"10.1016\/j.bmc.2016.08.028","volume":"24","author":"JD Zolnierczyk","year":"2016","unstructured":"Zolnierczyk JD, et al. In vitro antileukemic activity of novel adenosine derivatives bearing boron cluster modification. Bioorg Med Chem. 2016;24(21):5076\u201387.","journal-title":"Bioorg Med Chem"},{"issue":"1","key":"643_CR67","doi-asserted-by":"publisher","first-page":"14135","DOI":"10.1038\/s41598-019-50509-1","volume":"9","author":"A Poczta","year":"2019","unstructured":"Poczta A, et al. Antileukemic activity of novel adenosine derivatives. Sci Rep. 2019;9(1):14135.","journal-title":"Sci Rep"},{"key":"643_CR68","unstructured":"Pei S et al. Monocytic subclones confer resistance to venetoclax-based therapy in acute myeloid leukemia patients. Cancer Discovery 2020: CD-19-0710."},{"issue":"3","key":"643_CR69","doi-asserted-by":"publisher","first-page":"708","DOI":"10.3324\/haematol.2018.214882","volume":"105","author":"H Kuusanmaki","year":"2020","unstructured":"Kuusanmaki H, et al. Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia. Haematologica. 2020;105(3):708\u201320.","journal-title":"Haematologica"},{"issue":"7","key":"643_CR70","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617\u201329.","journal-title":"N Engl J Med"},{"issue":"24","key":"643_CR71","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1182\/blood.2020004856","volume":"135","author":"AH Wei","year":"2020","unstructured":"Wei AH, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020;135(24):2137\u201345.","journal-title":"Blood"},{"key":"643_CR72","doi-asserted-by":"crossref","unstructured":"\u2022 Montalban-Bravo G, et al. Activity of venetoclax-based therapy in chronic myelomonocytic leukemia. Leukemia. 2021;35(5):1494\u20139. Likewise, one of the few existing studies of novel therapy explicitly reporting outcomes in CMML-BP.","DOI":"10.1038\/s41375-021-01240-2"},{"issue":"5","key":"643_CR73","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.ccr.2006.03.027","volume":"9","author":"M Certo","year":"2006","unstructured":"Certo M, et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell. 2006;9(5):351\u201365.","journal-title":"Cancer Cell"},{"key":"643_CR74","doi-asserted-by":"crossref","unstructured":"Salhotra A, et al. Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (HMA-Ven) or liposomal daunorubicin-cytarabine (CPX-351). Am J Hematol. 2021.","DOI":"10.1002\/ajh.26157"},{"issue":"22","key":"643_CR75","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1182\/blood.V114.22.118.118","volume":"114","author":"S Faderl","year":"2009","unstructured":"Faderl S, et al. Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. Blood. 2009;114(22):118\u2013118.","journal-title":"Blood"},{"issue":"5","key":"643_CR76","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1177\/1352458510391344","volume":"17","author":"S Cook","year":"2011","unstructured":"Cook S, et al. Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study. Mult Scler. 2011;17(5):578\u201393.","journal-title":"Mult Scler"},{"issue":"3","key":"643_CR77","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S1474-4422(14)70005-5","volume":"13","author":"TP Leist","year":"2014","unstructured":"Leist TP, et al. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. Lancet Neurol. 2014;13(3):257\u201367.","journal-title":"Lancet Neurol"},{"issue":"26","key":"643_CR78","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1056\/NEJMoa2004444","volume":"383","author":"AH Wei","year":"2020","unstructured":"Wei AH, et al. Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission. N Engl J Med. 2020;383(26):2526\u201337.","journal-title":"N Engl J Med"},{"issue":"21","key":"643_CR79","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1182\/blood.V118.21.578.578","volume":"118","author":"PG Smith","year":"2011","unstructured":"Smith PG, et al. Azacitidine\/decitabine synergism with the NEDD8-activating enzyme inhibitor MLN4924 in pre-clinical AML models. Blood. 2011;118(21):578\u2013578.","journal-title":"Blood"},{"key":"643_CR80","doi-asserted-by":"crossref","unstructured":"Sekeres MA, et al. Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS\/CMML or low-blast AML. Leukemia. 2021.","DOI":"10.1038\/s41375-021-01125-4"},{"issue":"12","key":"643_CR81","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/cdd.2015.74","volume":"22","author":"KL Knorr","year":"2015","unstructured":"Knorr KL, et al. MLN4924 induces Noxa upregulation in acute myelogenous leukemia and synergizes with Bcl-2 inhibitors. Cell Death Differ. 2015;22(12):2133\u201342.","journal-title":"Cell Death Differ"},{"issue":"1","key":"643_CR82","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/jha2.2","volume":"1","author":"P Torka","year":"2020","unstructured":"Torka P, et al. Pevonedistat, a NEDD8-activating enzyme inhibitor, induces apoptosis and augments efficacy of chemotherapy and small molecule inhibitors in pre-clinical models of diffuse large B-cell lymphoma. EJHaem. 2020;1(1):122\u201332.","journal-title":"EJHaem"},{"issue":"Supplement_1","key":"643_CR83","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1182\/blood-2019-123068","volume":"134","author":"BN Smith","year":"2019","unstructured":"Smith BN, et al. Pevonedistat, a Nedd-8 activating enzyme inhibitor, upregulates NOXA to increase effectiveness of azacitidine and venetoclax in preclinical models of acute myelogenous leukemia. Blood. 2019;134(Supplement_1):1380.","journal-title":"Blood."},{"key":"643_CR84","doi-asserted-by":"crossref","unstructured":"Short N, Bose P, Dinardo C, Garcia-Manero G, Muftuoglu M, Alaniz Z, Patel K, Montalban-Bravo G, Jain J, Alvarado Y, Jabbour E, Andreeff M, Delumpa R, Kantarjian H, Cortes J. Preliminary results of a phase I\/II study of azacitidine, venetoclax and pevonedistat in patients with secondary acute myeloid leukemia who are unfit for intensive chemotherapy. 25th Congress of the European Hematology Association Virtual Edition, 2020.","DOI":"10.1182\/blood-2021-153682"},{"issue":"5","key":"643_CR85","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1111\/bph.12998","volume":"172","author":"M El-Mesery","year":"2015","unstructured":"El-Mesery M, et al. MLN4924 sensitizes monocytes and maturing dendritic cells for TNF-dependent and -independent necroptosis. Br J Pharmacol. 2015;172(5):1222\u201336.","journal-title":"Br J Pharmacol"},{"issue":"2","key":"643_CR86","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1093\/rheumatology\/kev294","volume":"55","author":"A Mekinian","year":"2016","unstructured":"Mekinian A, et al. Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study. Rheumatology (Oxford). 2016;55(2):291\u2013300.","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"643_CR87","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1182\/blood.2020007897","volume":"137","author":"W Xiao","year":"2021","unstructured":"Xiao W, et al. Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia. Blood. 2021;137(10):1377\u201391.","journal-title":"Blood"},{"key":"643_CR88","doi-asserted-by":"publisher","unstructured":"El Achi H, et al. CD123 as a biomarker in hematolymphoid malignancies: principles of detection and targeted therapies. Cancers (Basel). 2020;12(11):3087. https:\/\/doi.org\/10.3390\/cancers12113087.","DOI":"10.3390\/cancers12113087"},{"key":"643_CR89","doi-asserted-by":"crossref","unstructured":"Jen EY, Gao X, Li L, et al. FDA approval summary: tagraxofusp-erzs for treatment of blastic plasmacytoid dendritic cell neoplasm. Clin Cancer Res. 2020;26(3):532\u20136.","DOI":"10.1158\/1078-0432.CCR-19-2329"},{"issue":"3","key":"643_CR90","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.hoc.2020.01.005","volume":"34","author":"D Hammond","year":"2020","unstructured":"Hammond D, Pemmaraju N. Tagraxofusp for blastic plasmacytoid dendritic cell neoplasm. Hematol Oncol Clin North Am. 2020;34(3):565\u201374.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"15_suppl","key":"643_CR91","doi-asserted-by":"publisher","first-page":"7059","DOI":"10.1200\/JCO.2019.37.15_suppl.7059","volume":"37","author":"MM Patnaik","year":"2019","unstructured":"Patnaik MM, et al. Results from ongoing phase 1\/2 clinical trial of tagraxofusp (SL-401) in patients with relapsed\/refractory chronic myelomonocytic leukemia (CMML). Journal of Clinical Oncology. 2019;37(15_suppl):7059.","journal-title":"Journal of Clinical Oncology."},{"issue":"Supplement 1","key":"643_CR92","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1182\/blood-2020-139903","volume":"136","author":"N Pemmaraju","year":"2020","unstructured":"Pemmaraju N, et al. Clinical profile of IMGN632, a novel CD123-targeting antibody-drug conjugate (ADC), in patients with relapsed\/refractory (R\/R) blastic plasmacytoid dendritic cell neoplasm (BPDCN). Blood. 2020;136(Supplement 1):11\u20133.","journal-title":"Blood"},{"issue":"Supplement 1","key":"643_CR93","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1182\/blood-2020-136791","volume":"136","author":"VM Kuruvilla","year":"2020","unstructured":"Kuruvilla VM, et al. Combining IMGN632, a novel CD123-targeting antibody drug conjugate with azacitidine and venetoclax facilitates apoptosis in vitro and prolongs survival in vivo in AML models. Blood. 2020;136(Supplement 1):32\u20133.","journal-title":"Blood"},{"issue":"1","key":"643_CR94","doi-asserted-by":"publisher","first-page":"5341","DOI":"10.1038\/s41467-018-07551-w","volume":"9","author":"AE Tron","year":"2018","unstructured":"Tron AE, et al. Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia. Nat Commun. 2018;9(1):5341.","journal-title":"Nat Commun"},{"issue":"4","key":"643_CR95","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1158\/1078-0432.CCR-19-1853","volume":"26","author":"J Cidado","year":"2020","unstructured":"Cidado J, et al. AZD4573 Is a Highly Selective CDK9 Inhibitor That Suppresses MCL-1 and Induces Apoptosis in Hematologic Cancer Cells. Clin Cancer Res. 2020;26(4):922\u201334.","journal-title":"Clin Cancer Res"},{"key":"643_CR96","doi-asserted-by":"crossref","unstructured":"Janne P, Rybkin Il, Spira AI, et al. KRYSTAL-1: Activity and safety of adagrasib (MRTX849) in advanced\/metastatic non-small-cell lung cancer harboring KRAS G12C mutation. 2020: EORTC-NCI-AACR Symposium. Abstract LBA3. Presented October 25, 2020.","DOI":"10.1016\/S0959-8049(20)31076-5"},{"issue":"10","key":"643_CR97","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1038\/jid.2015.198","volume":"135","author":"C Posch","year":"2015","unstructured":"Posch C, et al. Combined inhibition of MEK and Plk1 has synergistic antitumor activity in NRAS mutant melanoma. J Invest Dermatol. 2015;135(10):2475\u201383.","journal-title":"J Invest Dermatol"},{"issue":"12","key":"643_CR98","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1002\/cncr.29986","volume":"122","author":"G Borthakur","year":"2016","unstructured":"Borthakur G, et al. Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies. Cancer. 2016;122(12):1871\u20139.","journal-title":"Cancer"},{"issue":"2","key":"643_CR99","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/bjh.12518","volume":"163","author":"C Muller-Tidow","year":"2013","unstructured":"Muller-Tidow C, et al. A randomized, open-label, phase I\/II trial to investigate the maximum tolerated dose of the Polo-like kinase inhibitor BI 2536 in elderly patients with refractory\/relapsed acute myeloid leukaemia. Br J Haematol. 2013;163(2):214\u201322.","journal-title":"Br J Haematol"},{"issue":"9","key":"643_CR100","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1182\/blood-2014-03-560557","volume":"124","author":"H Dohner","year":"2014","unstructured":"Dohner H, et al. Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy. Blood. 2014;124(9):1426\u201333.","journal-title":"Blood"},{"issue":"6","key":"643_CR101","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1111\/bjh.15204","volume":"184","author":"OG Ottmann","year":"2019","unstructured":"Ottmann OG, et al. Phase I dose-escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed\/refractory acute myeloid leukaemia. Br J Haematol. 2019;184(6):1018\u201321.","journal-title":"Br J Haematol"},{"issue":"23","key":"643_CR102","doi-asserted-by":"publisher","first-page":"6132","DOI":"10.1158\/1078-0432.CCR-20-2586","volume":"26","author":"AM Zeidan","year":"2020","unstructured":"Zeidan AM, et al. A phase Ib study of onvansertib, a novel oral PLK1 inhibitor, in combination therapy for patients with relapsed or refractory acute myeloid leukemia. Clin Cancer Res. 2020;26(23):6132\u201340.","journal-title":"Clin Cancer Res"},{"key":"643_CR103","doi-asserted-by":"publisher","first-page":"587554","DOI":"10.3389\/fonc.2021.587554","volume":"11","author":"X Zhang","year":"2021","unstructured":"Zhang X, et al. Polo-like kinase 4\u2019s critical role in cancer development and strategies for Plk4-targeted therapy. Front Oncol. 2021;11:587554.","journal-title":"Front Oncol."},{"issue":"4","key":"643_CR104","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/s41416-019-0517-3","volume":"121","author":"ZW Veitch","year":"2019","unstructured":"Veitch ZW, et al. Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trial. Br J Cancer. 2019;121(4):318\u201324.","journal-title":"Br J Cancer"},{"issue":"Supplement 1","key":"643_CR105","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1182\/blood-2020-138822","volume":"136","author":"T Murphy","year":"2020","unstructured":"Murphy T, et al. Preliminary results from a phase 1 study of Cfi-400495, a PLK4 inhibitor, in patients with acute myeloid leukemia and high risk MDS. Blood. 2020;136(Supplement 1):1\u20132.","journal-title":"Blood"},{"issue":"7728","key":"643_CR106","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/s41586-018-0615-z","volume":"562","author":"M Deng","year":"2018","unstructured":"\u2022\u2022 Deng M, et al. LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration. Nature. 2018;562(7728):605\u20139. Toghether, these provide translational background for the most exciting future target in CMML-BP.","journal-title":"Nature"},{"issue":"10","key":"643_CR107","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1016\/j.ymthe.2018.08.001","volume":"26","author":"S John","year":"2018","unstructured":"John S, et al. A novel anti-LILRB4 CAR-T cell for the treatment of monocytic AML. Mol Ther. 2018;26(10):2487\u201395.","journal-title":"Mol Ther"},{"issue":"1","key":"643_CR108","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/cyto.b.21050","volume":"84","author":"H Dobrowolska","year":"2013","unstructured":"Dobrowolska H, et al. Expression of immune inhibitory receptor ILT3 in acute myeloid leukemia with monocytic differentiation. Cytometry B Clin Cytom. 2013;84(1):21\u20139.","journal-title":"Cytometry B Clin Cytom"},{"key":"643_CR109","doi-asserted-by":"publisher","unstructured":"Dobrowolska H. Expression of inhibitory receptor ILT3 on normal hematopoietic stem cells and leukemic progenitors. J Cell Sci Ther. 2013;4:4. https:\/\/doi.org\/10.4172\/2157-7013.S1.025.","DOI":"10.4172\/2157-7013.S1.025"},{"issue":"8","key":"643_CR110","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1158\/2326-6066.CIR-19-0036","volume":"7","author":"X Gui","year":"2019","unstructured":"Gui X, et al. Disrupting LILRB4\/APOE interaction by an efficacious humanized antibody reverses T-cell suppression and blocks AML development. Cancer Immunol Res. 2019;7(8):1244\u201357.","journal-title":"Cancer Immunol Res"},{"issue":"3","key":"643_CR111","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/s41423-019-0321-2","volume":"17","author":"Z Li","year":"2020","unstructured":"Li Z, et al. LILRB4 ITIMs mediate the T cell suppression and infiltration of acute myeloid leukemia cells. Cell Mol Immunol. 2020;17(3):272\u201382.","journal-title":"Cell Mol Immunol"},{"issue":"6","key":"643_CR112","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1080\/10428194.2020.1723014","volume":"61","author":"KS Chien","year":"2020","unstructured":"Chien KS, et al. LILRB4 expression in chronic myelomonocytic leukemia and myelodysplastic syndrome based on response to hypomethylating agents. Leuk Lymphoma. 2020;61(6):1493\u20139.","journal-title":"Leuk Lymphoma"},{"key":"643_CR113","doi-asserted-by":"crossref","unstructured":"Singh L, et al. ILT3 (LILRB4) promotes the immunosuppressive function of tumor-educated human monocytic myeloid-derived suppressor cells. Mol Cancer Res. 2020.","DOI":"10.1158\/1541-7786.MCR-20-0622"},{"key":"643_CR114","doi-asserted-by":"crossref","unstructured":"Anami Y, et al. LILRB4-targeting antibody-drug conjugates for the treatment of acute myeloid leukemia. Mol Cancer Ther. 2020;19(11):2330\u20139.","DOI":"10.1158\/1535-7163.MCT-20-0407"},{"issue":"Supplement 1","key":"643_CR115","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1182\/blood-2020-137665","volume":"136","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, et al. A First-in-human (FIH) phase 1 study of the anti-LILRB4 antibody IO-202 in relapsed\/refractory (R\/R) myelomonocytic and monocytic acute myeloid leukemia (AML) and R\/R chronic myelomonocytic leukemia (CMML). Blood. 2020;136(Supplement 1):19\u201320.","journal-title":"Blood"},{"issue":"14","key":"643_CR116","doi-asserted-by":"publisher","first-page":"3932","DOI":"10.1182\/blood-2010-10-311019","volume":"118","author":"AM Jankowska","year":"2011","unstructured":"Jankowska AM, et al. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood. 2011;118(14):3932\u201341.","journal-title":"Blood"},{"issue":"12","key":"643_CR117","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.3324\/haematol.2012.065375","volume":"97","author":"S Schnittger","year":"2012","unstructured":"Schnittger S, et al. Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic\/myeloproliferative disorders: an analysis of 636 cases. Haematologica. 2012;97(12):1890\u20134.","journal-title":"Haematologica"},{"key":"643_CR118","doi-asserted-by":"crossref","unstructured":"Kohlmann A, et al. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. J Clin Oncol. 2010;28(24): 3858-65.","DOI":"10.1200\/JCO.2009.27.1361"},{"issue":"3","key":"643_CR119","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1182\/blood-2007-01-066076","volume":"110","author":"B Sargin","year":"2007","unstructured":"Sargin B, et al. Flt3-dependent transformation by inactivating c-Cbl mutations in AML. Blood. 2007;110(3):1004\u201312.","journal-title":"Blood"},{"issue":"42","key":"643_CR120","doi-asserted-by":"publisher","first-page":"32596","DOI":"10.1074\/jbc.M110.106161","volume":"285","author":"MS Fernandes","year":"2010","unstructured":"Fernandes MS, et al. Novel oncogenic mutations of CBL in human acute myeloid leukemia that activate growth and survival pathways depend on increased metabolism. J Biol Chem. 2010;285(42):32596\u2013605.","journal-title":"J Biol Chem"},{"issue":"4","key":"643_CR121","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/bjh.16092","volume":"187","author":"E Weisberg","year":"2019","unstructured":"Weisberg E, et al. Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies. Br J Haematol. 2019;187(4):488\u2013501.","journal-title":"Br J Haematol"},{"issue":"19","key":"643_CR122","doi-asserted-by":"publisher","first-page":"6128","DOI":"10.1158\/1078-0432.CCR-08-3180","volume":"15","author":"T Narita","year":"2009","unstructured":"Narita T, et al. Identification of a novel small molecule HIF-1alpha translation inhibitor. Clin Cancer Res. 2009;15(19):6128\u201336.","journal-title":"Clin Cancer Res"},{"issue":"17","key":"643_CR123","doi-asserted-by":"publisher","first-page":"10052","DOI":"10.1111\/jcmm.15612","volume":"24","author":"R Hallal","year":"2020","unstructured":"Hallal R, et al. Acriflavine targets oncogenic STAT5 signaling in myeloid leukemia cells. J Cell Mol Med. 2020;24(17):10052\u201362.","journal-title":"J Cell Mol Med"},{"key":"643_CR124","doi-asserted-by":"crossref","unstructured":"Nehme R, et al. Repurposing of acriflavine to target chronic myeloid leukemia treatment. Curr Med Chem. 2021;28(11):2218\u201333.","DOI":"10.2174\/0929867327666200908114411"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-021-00643-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11899-021-00643-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-021-00643-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,8]],"date-time":"2024-09-08T03:17:58Z","timestamp":1725765478000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11899-021-00643-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,9]]},"references-count":124,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["643"],"URL":"https:\/\/doi.org\/10.1007\/s11899-021-00643-3","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,9]]},"assertion":[{"value":"16 June 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}